Terapi Psoriasis di Era Pandemi COVID-19
DOI:
https://doi.org/10.55175/cdk.v48i7.90Keywords:
Autoimun, pandemi COVID-19, psoriasis, terapiAbstract
Psoriasis merupakan penyakit inflamasi kronis kulit dengan predisposisi genetik dan autoimun yang kuat. Prevalensi psoriasis di seluruh dunia adalah 0,09% sampai 5,1%, bervariasi antar negara. Psoriasis dikarakteristikkan dengan lesi plak eritematosa yang dilapisi skuama tebal putih keabuan, biasanya memiliki predileksi simestris di siku, lutut, trunk, dan scalp. Terapi sebagian besar menggunakan imunomodulator atau imunosupresan untuk psoriasis derajat sedang hingga berat. Sudah terdapat beberapa penelitian efek samping dan rekomendasi dosis obatobatan di era COVID-19. Penggunaan terapi tersebut dalam era pandemi COVID-19 harus hati-hati dan tetap menjaga imunitas pasien.
Psoriasis is a chronic skin inflammatory disease with a strong genetic and autoimmune predisposition. The prevalence of psoriasis worldwide is 0.09% to 5.1%, varies among countries. Psoriasis is characterized by erythematous plaque lesions covered in thick gray-white scales, usually have a symmetrical predilection on the elbows, knees, trunk, and scalp. Immunomodulators or immunosuppressants are commonly used for moderate to severe psoriasis. There have been several studies on side effects and recommendations for the necessary dosage adjustments in the era of the COVID-19 pandemic. Careful use is important to maintain patient’s immunity
Downloads
References
Korman NJ. Management of psoriasis as a systemic disease: What is the evidence? Br J Dermatol. 2020;182(4):840–8.
Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):205–12.
Kim WB, Jerome D, Yeung J. Diagnosis and management of psoriasis. Can Fam Physician. 2017;63(4):278–85.
Kunz M, Simon JC, Saalbach A. Psoriasis: Obesity and fatty acids. Front Immunol. 2019;10:1807.
Ogawa E, Sato Y, Minagawa A, Okuyama R. Pathogenesis of psoriasis and development of treatment. J Dermatol. 2018;45(3):264–72.
Kang Sewon. Fitzpatrick’s dermatology [2-Volume Set]-McGraw-Hill Education. 2019
Desai K, Miteva M, Romanelli P. Challenges in managing immunosuppressive therapies for psoriasis during the COVID-19 pandemic. Cell R4. 2020;8:2852.
Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmunity. 2020;109:102433.
Gisondi P, Facheris P, Dapavo P, Piaserico S, Conti A, Naldi L, et al. The impact of the COVID ‐19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experience. Br J Dermatol. 2020;183(2):373–4.
Lee JS, Oh JS, Kim YG, Lee CK, Yoo B, Hong S. Methotrexate-related toxicity in patients with rheumatoid arthritis and renal dysfunction. Rheumatol Int. 2020;40(5):765–70.
Lebwohl M, Rivera-Oyola R, Murrell DF. Should biologics for psoriasis be interrupted in the era of COVID-19? J Am Acad Dermatol. 2020;82(5):1217–8.
Sadeghinia A, Daneshpazhooh M. Immunosuppressive drugs for patients with psoriasis during the COVID -19 pandemic era. A review. Dermatol Ther [Internet]. 2020 Nov 10 [cited 2020 Nov 28]. Available from: https://onlinelibrary.wiley.com/doi/10.1111/dth.14498
Rademaker M, Baker C, Foley P, Sullivan J, Wang C. Advice regarding COVID-19 and use of immunomodulators, in patients with severe dermatological diseases. Australas J Dermatol. 2020;61(2):158–9.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Cermin Dunia Kedokteran
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
